Arbutus Biopharma Corp (ABUS) цена на акцијата и вести

Почетна страницаABUS • NASDAQ

Arbutus Biopharma Corp

4,26 $

16 мар., 08:20:34 GMT-4 · USD · NASDAQ · Оградување

АкцијаСе тргува во САДСо седиште во САД

Прет. посл. цена

4,26 $

Годишен опсег

2,71 $ - 5,10 $

Пазарна капитализација

819,30 М USD

Просечен обем

2,67 мил.

Сооднос Ц/З

Принос од дивиденда

Примарна берза

NASDAQ

Вести за пазарот

GlobeNewswire

пред 17 минути

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

Cycurion (Nasdaq: CYCU) Announces Definitive Agreement to Acquire Federal Cybersecurity Firm and Reports Record Contracted Backlog Exceeding $150 Million

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

CareCloud to Ring Nasdaq Closing Bell on May 19, 2026 and Host Analyst Day at Nasdaq MarketSite in New York City

CCLD

7,90 %

Информации

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

Главен извршен директор

William H. Collier

Основана на

2007

Седиште

Warminster Township, Пенсилванија
Соединети Американски Држави

Вебсајт

arbutusbio.com

Вработени